Inflammatory bowel disease (IBD), affecting an estimated 6–8 million people worldwide, may soon be monitored with a simple ...

ORLANDO -- Patients with inflammatory bowel disease (IBD) reported mostly favorable responses with the use of mail-order kits for stool sample collections, according to a survey study. Among survey ...

Promising findings by researchers at Baylor College of Medicine and collaborating institutions could lead to the development of a non-invasive stool test and a new therapy for endometriosis, a painful ...

Medicare should cover a parasite poop test when medically necessary, usually when a person has symptoms of gastroenteritis or a history of exposure to a parasite. Laboratory technicians perform a ...

Noninvasive surveillance with multitarget stool DNA testing or fecal immunochemical testing (FIT) could potentially match colonoscopy for reducing long-term ...

A recent prospective cross-sectional study in Thailand demonstrates that multitarget stool DNA testing is highly sensitive and specific for detecting colorectal cancer (CRC) among Thai individuals.

Stool-based DNA testing can help bridge CRC screening gaps between rural and urban populations by providing timely follow-up. The study found no significant difference in follow-up times for ...

October 9, 2008 — Stool DNA testing is a new approach to screening for colorectal cancer, but it is an evolving technology. A study has found that the first-generation stool DNA test (SDT-1) is not ...

Q: My doctor always encourages me to do a colonoscopy for colorectal cancer screening. But I have friends who just do a stool test at home, which seems easier. Why should I go through the hassle of a ...

Prospective multicentre study highlights the potential of the Xpert MTB/Ultra stool test for diagnosing tuberculosis in people living with HIV “People living with HIV are at higher risk of developing ...

Please provide your email address to receive an email when new articles are posted on . The multitarget stool DNA test had a positive predictive value of 31.4% for detecting advanced adenomas.

INDIANAPOLIS -- A study of more than 21,000 average risk patients at 186 sites across the U.S., led by Regenstrief Institute and Indiana University School of Medicine research scientist Thomas ...